Rapid Antibacterial Activity Assessment of Chimeric Lysins

Jin-Mi Park,Jun-Hyun Kim,Gun Kim,Hun-Ju Sim,Sun-Min Ahn,Kang-Seuk Choi,Hyuk-Joon Kwon
DOI: https://doi.org/10.3390/ijms25042430
IF: 5.6
2024-02-20
International Journal of Molecular Sciences
Abstract:Various chimeric lysins have been developed as efficacious antibiotics against multidrug-resistant bacteria, but direct comparisons of their antibacterial activities have been difficult due to the preparation of multiple recombinant chimeric lysins. Previously, we reported an Escherichia coli cell-free expression method to better screen chimeric lysins against Staphylococcus aureus, but we still needed to increase the amounts of expressed proteins enough to be able to detect them non-isotopically for quantity comparisons. In this study, we improved the previous cell-free expression system by adding a previously reported artificial T7 terminator and reversing the different nucleotides between the T7 promoter and start codon to those of the T7 phage. The new method increased the expressed amount of chimeric lysins enough for us to detect them using Western blotting. Therefore, the qualitative comparison of activity between different chimeric lysins has become possible via the adjustment of the number of variables between samples without protein purification. We applied this method to select more active chimeric lysins derived from our previously reported chimeric lysin (ALS2). Finally, we compared the antibacterial activities of our selected chimeric lysins with reported chimeric lysins (ClyC and ClyO) and lysostaphin and determined the rank orders of antibacterial activities on different Staphylococcus aureus strains in our experimental conditions.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper focuses on the rapid evaluation of chimeric lysins in combating multidrug-resistant bacteria, particularly Staphylococcus aureus. The researchers improved the cell-free expression system in Escherichia coli by incorporating an artificial T7 terminator and adjusting the nucleotides between the promoter and start codon to enhance the expression level of chimeric lysins. This improvement enabled a direct comparison of the quantity of different chimeric lysins using Western blotting, allowing for quantitative analysis of their antibacterial activity. Using this method, the researchers screened and optimized derivatives of the previously reported chimeric lysin ALS2 by deleting its amidase domain and optimizing the linker chain to enhance its antibacterial activity. They also compared the selected chimeric lysin (including ALS2-dA-L25) with other known chimeric lysins (such as ClyC, ClyO) and lysostaphin, a Staphylococcus lytic enzyme, in terms of antibacterial activity. The researchers determined the ranking of antibacterial activity against different strains of Staphylococcus aureus under experimental conditions. The results of the paper demonstrate that the improved cell-free expression system can enhance the expression efficiency of lysins and facilitate the screening of chimeric lysin variants with stronger antibacterial activity. These findings are significant for the development of new generation antibiotics against resistant bacteria.